Masimo Corporation (NASDAQ: MASI) announced that its shareholders voted to approve the merger agreement with Danaher Corporation (NYSE: DHR) at a special meeting held May 1, 2026.

Under the merger terms, each Masimo share will be converted into $180 in cash. The transaction was originally announced through an agreement dated February 16, 2026, involving Masimo, Danaher, and Mobius Merger Sub, Inc.

"We thank our shareholders for their strong support of this important milestone for Masimo," said Katie Szyman, Chief Executive Officer of Masimo. "The Merger delivers compelling value and positions Masimo for continued global growth as an independent operating company within Danaher's Diagnostics segment."

The transaction remains subject to customary closing conditions, including regulatory approvals and clearances. Masimo expects the merger to close in 2026.

Masimo develops patient monitoring technologies including sensors, patient monitors, and automation solutions. The company's pulse oximetry technology is used on more than 200 million patients annually and operates in all top 10 U.S. hospitals according to the 2025 Newsweek World's Best Hospitals listing.

The information is based on a company press release statement.